Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy

To observe the change of urinary monocyte chemottractant protein-1 (MCP-1) in patients with diabetic nephropathy (DN), and to explore the therapeutic effect and mechanism of triptolide (TL) in treating DN. Thirty-five patients in the treated group were treated with TL plus benazepril and thirty two...

Full description

Saved in:
Bibliographic Details
Published inZhongguo Zhong xi yi jie he za zhi Vol. 25; no. 5; p. 416
Main Authors Song, Hai-xiang, Gong, Jing, Chen, Wen
Format Journal Article
LanguageChinese
Published China 01.05.2005
Subjects
Adult
Aged
Chemokine CCL2 - urine
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - urine
Diterpenes - therapeutic use
Epoxy Compounds
Female
Humans
Immunosuppressive Agents - therapeutic use
Male
Middle Aged
Phenanthrenes - therapeutic use
Phytotherapy
Prospective Studies
Online AccessGet more information

Cover

More Information
Summary:To observe the change of urinary monocyte chemottractant protein-1 (MCP-1) in patients with diabetic nephropathy (DN), and to explore the therapeutic effect and mechanism of triptolide (TL) in treating DN. Thirty-five patients in the treated group were treated with TL plus benazepril and thirty two patients in the control group were treated with benazepril alone for six months. The change of urinary MCP-1 was measured before and after treatment. Level of urinary MCP-1 in DN patients was significantly higher than that in healthy subjects (P < 0.01), but it could be significantly decreased after TL treatment, showing significant difference as compared with that in the control group (P < 0.05). Determination of urinary MCP-1 level is beneficial to know the degree of kidney inflammation in DN patients. TL can inhibit inflammatory reaction to decrease the level of urinary MCP-1, and thus improve the renal function.
ISSN:1003-5370